NCT01649817

Brief Summary

This multicenter, retrospective observational study will evaluate compliance an reasons for withdrawal in patients with moderate to severe active rheumatoid arthritis on treatment with intravenous RoActemra/Actemra (tocilizumab) in daily clinical practice. Data will be collected from each eligible patient over a period of 6 months.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
183

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2012

Shorter than P25 for all trials

Geographic Reach
1 country

24 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2012

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

July 23, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 25, 2012

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2013

Completed
Last Updated

November 2, 2016

Status Verified

November 1, 2016

Enrollment Period

1 year

First QC Date

July 23, 2012

Last Update Submit

November 1, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • Percentage of patients on RoActemra/Actemra at 6 months after initiating treatment

    12 months

Secondary Outcomes (3)

  • Frequency of withdrawal (according to reasons)

    12 months

  • Frequency of dose modifications

    12 months

  • Change in disease activity (DAS28)

    from baseline to Month 6 or withdrawal, whichever comes first

Study Arms (1)

Cohort

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Rheumatoid arthritis patients suitable for treatment with RoActemra/Actemra according to SPC

You may qualify if:

  • Adult patients, \>/= 18 years of age
  • Moderate to severe rheumatoid arthritis according to the revised 1987 ACR criteria at baseline
  • RoActemra/Actemra treatment must have been initiated 6 months prior to ICF signing
  • Patient eligible according to the summary of product characteristics (SPC) and routine clinical practice/European recommendations for the use of biologic DMARDs for the treatment of rheumatoid arthritis

You may not qualify if:

  • Rheumatic autoimmune disease other than RA
  • Participation in interventional clinical trials during the observational period

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (24)

Unknown Facility

Agios Dimitrios, 17343, Greece

Location

Unknown Facility

Agía Paraskeví, 15342, Greece

Location

Unknown Facility

Argiroupoli, 16452, Greece

Location

Unknown Facility

Athens, 11473, Greece

Location

Unknown Facility

Athens, 11521, Greece

Location

Unknown Facility

Athens, 155 62, Greece

Location

Unknown Facility

Athens, Greece

Location

Unknown Facility

Chalandri, Greece

Location

Unknown Facility

Chania, 73134, Greece

Location

Unknown Facility

Corinth, 20100, Greece

Location

Unknown Facility

Eleusina, 19200, Greece

Location

Unknown Facility

Herakleio, 71307, Greece

Location

Unknown Facility

Ioannina, 455 00, Greece

Location

Unknown Facility

Kifissia, Greece

Location

Unknown Facility

Peristeri, 12934, Greece

Location

Unknown Facility

Peuki, 15121, Greece

Location

Unknown Facility

Rethymno, 74100, Greece

Location

Unknown Facility

Serres, 62122, Greece

Location

Unknown Facility

Thessaloniki, 54621, Greece

Location

Unknown Facility

Thessaloniki, 54622, Greece

Location

Unknown Facility

Thessaloniki, 54623, Greece

Location

Unknown Facility

Thessaloniki, 54624, Greece

Location

Unknown Facility

Thessaloniki, Greece

Location

Unknown Facility

Volos, 38221, Greece

Location

MeSH Terms

Conditions

Arthritis, Rheumatoid

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System Diseases

Study Officials

  • Clinical Trials

    Hoffmann-La Roche

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 23, 2012

First Posted

July 25, 2012

Study Start

May 1, 2012

Primary Completion

May 1, 2013

Study Completion

May 1, 2013

Last Updated

November 2, 2016

Record last verified: 2016-11

Locations